Thermo Fisher Scientific (BSP:TMOS34) Altman Z2-Score: 3.63 (As of Jun. 26, 2026) — Near Median


BSP:TMOS34 Thermo Fisher Scientific Inc BSP:TMOS34
74 GF Score
Price R$54.95
GF Value R$63.36
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Thermo Fisher Scientific Altman Z2-Score?

Thermo Fisher Scientific BSP:TMOS34 +3.19% 74 Altman Z2-Score is 3.63 as of Jun. 26, 2026, which is 3% above its 10-year median of 3.52. GuruFocus rates BSP:TMOS34 with a GF Score™ of 74/100 and a GF Value™ of R$63.36 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Thermo Fisher Scientific ranks better than 62.56% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Thermo Fisher Scientific has a Altman Z2-Score of 3.63, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Thermo Fisher Scientific's Altman Z2-Score or its related term are showing as below:

BSP:TMOS34' s Altman Z2-Score Range Over the Past 10 Years
Min: 2.28   Med: 3.52   Max: 5.13
Current: 3.61

During the past 13 years, Thermo Fisher Scientific's highest Altman Z2-Score was 5.13. The lowest was 2.28. And the median was 3.52.


Thermo Fisher Scientific  (BSP:TMOS34) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Thermo Fisher Scientific Altman Z2-Score Related Terms


Thermo Fisher Scientific Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Thermo Fisher Scientific's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thermo Fisher Scientific Altman Z2-Score Chart

Thermo Fisher Scientific Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.13 3.42 3.73 4.05 4.07

Thermo Fisher Scientific Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.08 4.17 3.87 4.07 3.61

BSP:TMOS34 vs DHR, IDXX, A: Altman Z2-Score Comparison

For the Diagnostics & Research subindustry, Thermo Fisher Scientific's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thermo Fisher Scientific Altman Z2-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Thermo Fisher Scientific's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Thermo Fisher Scientific's Altman Z2-Score falls into.


BSP:TMOS34
74GF Score
Thermo Fisher Scientific Inc BSP:TMOS34
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thermo Fisher Scientific Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Thermo Fisher Scientific's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.0679+3.26*0.5352+6.72*0.0811+1.05*0.8483
=3.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was R$592,414 Mil.
Total Current Assets was R$116,704 Mil.
Total Current Liabilities was R$76,462 Mil.
Retained Earnings was R$317,081 Mil.
Pre-Tax Income was 9068.126 + 11746.122 + 9792.838 + 9477.772 = R$40,085 Mil.
Interest Expense was -1851.278 + -1991.33 + -1860.961 + -2240.503 = R$-7,944 Mil.
Total Liabilities was R$320,156 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(116703.754 - 76461.982)/592414.318
=0.0679

X2=Retained Earnings/Total Assets
=317081.107/592414.318
=0.5352

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(40084.858 - -7944.072)/592414.318
=0.0811

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(271588.817 - 0)/320156.112
=0.8483

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Thermo Fisher Scientific has a Altman Z2-Score of 3.63 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 3.63 mean?
Thermo Fisher Scientific (BSP:TMOS34) has a Altman Z2-Score of 3.63 as of Jun. 26, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Thermo Fisher Scientific and its competitors. This is near median its historical median of 3.52. Over the past decade, Thermo Fisher Scientific's Altman Z2-Score has ranged from 2.28 to 5.13. According to the industry distribution chart, Thermo Fisher Scientific ranks #79 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 37.4%.
Is Thermo Fisher Scientific's Altman Z2-Score too high?
Thermo Fisher Scientific's current Altman Z2-Score of 3.63 is near median its 10-year median of 3.52. Over the past 10 years, this metric has ranged from a low of 2.28 to a high of 5.13. The Medical Diagnostics & Research industry median Altman Z2-Score is 1.66. Thermo Fisher Scientific's value of 3.63 is 118.7% above this industry median. Based on the distribution chart, Thermo Fisher Scientific ranks #79 out of 211 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Thermo Fisher Scientific has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Thermo Fisher Scientific's Altman Z2-Score compare to DHR and IDXX?
According to the Medical Diagnostics & Research industry distribution chart, Thermo Fisher Scientific ranks #79 out of 211 companies for Altman Z2-Score. This puts Thermo Fisher Scientific in the upper half of its industry. The industry median Altman Z2-Score is 1.66. Thermo Fisher Scientific's value of 3.63 is 118.7% above this benchmark. Historically, Thermo Fisher Scientific's own Altman Z2-Score has ranged from 2.28 to 5.13 over the past decade. While the company's 10-year median is 3.52 vs. the industry median of 1.66, Thermo Fisher Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Medical Diagnostics & Research company?
The median Altman Z2-Score among Medical Diagnostics & Research companies is 1.66, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thermo Fisher Scientific's current Altman Z2-Score of 3.63 is 118.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Thermo Fisher Scientific and its competitors. For the Medical Diagnostics & Research industry, the median Altman Z2-Score is 1.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thermo Fisher Scientific's current Altman Z2-Score is 3.63, which is near median its own 10-year median of 3.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thermo Fisher Scientific stock overvalued right now?
Based on GuruFocus' analysis, Thermo Fisher Scientific (BSP:TMOS34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$63.36, compared to a current price of R$54.95 — trading 13.3% below its estimated fair value. The current Altman Z2-Score is 3.63, which is near median its 10-year median of 3.52 and 118.7% above the Medical Diagnostics & Research industry median of 1.66. Thermo Fisher Scientific's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Thermo Fisher Scientific (BSP:TMOS34), the current Altman Z2-Score is 3.63 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Thermo Fisher Scientific (BSP:TMOS34) Overvalued in 2026?

Based on GuruFocus' analysis, Thermo Fisher Scientific stock appears to be undervalued. The current stock price of R$54.95 is trading 13.3% below its estimated GF Value™ of R$63.36. GuruFocus considers Thermo Fisher Scientific to be Modestly Undervalued.

Key valuation signals for BSP:TMOS34:

  • Altman Z2-Score: 3.63 (near median its 10-year median of 3.52)
  • GF Value™: R$63.36 vs. price of R$54.95 (13.3% below fair value)
  • GF Score™: 74/100 with 5 warning signs
  • Industry Position: 118.7% above the Medical Diagnostics & Research median (#79 of 211)

No single metric tells the full story. See the BSP:TMOS34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Thermo Fisher Scientific Business Description

Address 168 Third Avenue, Waltham, MA, USA, 02451
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
74GF Score

Get the complete analysis for BSP:TMOS34

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$54.95
Price
R$63.36
GF Value